Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study | Zendy

Jordan J. Feld | Zendy; Raoel Maan | Zendy; Stefan Zeuzem | Zendy; Alexander Kuo | Zendy; David R. Nelson | Zendy; Adrian M. Di Bisceglie | Zendy; Michael P. Manns | Zendy; Ken Sherman | Zendy; Lynn M. Frazier | Zendy; Richard K. Sterling | Zendy; Mark E. Mailliard | Zendy; Monica Schmidt | Zendy; Lucy Akushevich | Zendy; Monika Vainorius | Zendy; Michael Fried | Zendy

Open Access

Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study

Author(s) -

Jordan J. Feld,

Raoel Maan,

Stefan Zeuzem,

Alexander Kuo,

David R. Nelson,

Adrian M. Di Bisceglie,

Michael P. Manns,

Ken Sherman,

Lynn M. Frazier,

Richard K. Sterling,

Mark E. Mailliard,

Monica Schmidt,

Lucy Akushevich,

Monika Vainorius,

Michael Fried

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw387

Subject(s) - sofosbuvir , medicine , hepatitis c virus , cirrhosis , genotype , hepatitis c , hepacivirus , virology , virus , ribavirin , biochemistry , chemistry , gene

Sofosbuvir (SOF) is active against all hepatitis C virus (HCV) genotypes, and SOF-based therapies lead to high rates of sustained virologic response (SVR). However, genotype 3 (GT3) HCV remains a challenge with lower SVR rates reported, particularly in patients with cirrhosis. This study reports the effectiveness and safety of SOF-based therapy in patients with GT3 HCV treated in clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research